Michelle Lock
Vorstandsvorsitzender bei RELIEF THERAPEUTICS HOLDING SA
Profil
Ms. Michelle Lock is a Chief Executive Officer & Director at RELIEF THERAPEUTICS Holding SA. She is on the Board of Directors at RELIEF THERAPEUTICS Holding SA. Ms. Lock was previously employed as a Chief Operating Officer by Covis Pharma Holdings BV and a Senior Vice President, Head-Europe & International by Acceleron Pharma, Inc.
Aktive Positionen von Michelle Lock
| Unternehmen | Position | Beginn |
|---|---|---|
| RELIEF THERAPEUTICS HOLDING SA | Vorstandsvorsitzender | 01.11.2023 |
Ehemalige bekannte Positionen von Michelle Lock
| Unternehmen | Position | Ende |
|---|---|---|
Covis Pharma Holdings BV
 Covis Pharma Holdings BV Pharmaceuticals: MajorHealth Technology Covis Pharma Holdings BV engages in the marketing and distribution of therapeutic solutions for patients with life-threatening conditions and chronic illnesses. It offers its products under the Alvesco, Omnaris, Zetonna, Altoprev, Betapace, Betapace AF, Lanoxin, Sular, Prilosec, Zanaflex, Rilutek, Tizanidine Hydrochloride, Nisoldipine, and Riluzole brands. The company was founded in December 2011 and is headquartered in Zug, Switzerland. | Geschäftsführer | - |
| ACCELERON PHARMA INC. | Corporate Officer/Principal | - |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| RELIEF THERAPEUTICS HOLDING SA | Health Technology |
| Private Unternehmen | 2 |
|---|---|
Acceleron Pharma, Inc.
 Acceleron Pharma, Inc. BiotechnologyHealth Technology Acceleron Pharma, Inc. is a biopharmaceutical company, which engages in the discovery, development and commercialization of therapeutics to treat serious and rare diseases. Its product candidates include Luspatercept, designed to patients with chronic anemia associated within a wide range of blood diseases; ACE-083, designed for the treatment of focal muscle disorders; and Sotatercept, designed to treat pulmonary arterial hypertension. The company was founded by John L. Knopf and Thomas P. Maniatis in June 2003 and is headquartered in Cambridge, MA. | Health Technology |
Covis Pharma Holdings BV
Covis Pharma Holdings BV Pharmaceuticals: MajorHealth Technology Covis Pharma Holdings BV engages in the marketing and distribution of therapeutic solutions for patients with life-threatening conditions and chronic illnesses. It offers its products under the Alvesco, Omnaris, Zetonna, Altoprev, Betapace, Betapace AF, Lanoxin, Sular, Prilosec, Zanaflex, Rilutek, Tizanidine Hydrochloride, Nisoldipine, and Riluzole brands. The company was founded in December 2011 and is headquartered in Zug, Switzerland. | Health Technology |
